Pharmacy World and Science

, Volume 26, Issue 2, pp 110–113 | Cite as

A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs

  • Douwe de Boer
  • Ingrid Bosman


Objective: To collect data related to phenethylamine drugs-of-abuse of the 2C-series, to review possible health risks of their use and to discuss legal counter actions of authorities in the European Union (EU).

Settings: Dutch smartshops.

Methods: In the period of 1994–2002, all products that were claimed to contain synthetic drugs and sold in the smartshops, were purchased. The contents were analysed using analytical chemical technologies such as gas chromatography/mass spectrometry and nuclear magnetic resonance. Additionally, using computerised searches in relevant databases and checking cross-references, literature and documents were screened for scientific based information.

Results: All purchased products proved to be tablets, of which most of them contained one of the phenethylamine designer drugs 2C-B, 2C-T-2 or 2C-T-7. The different drugs were introduced on the Dutch smartshop market within time intervals of approximately three years. The information that was supplied on leaflets and accompanied the products sometimes appeared to be extensive, but was partly misleading and incorrect. Besides that, scientific based information in respect to health risks of drugs of the 2C-series and the detection of their abuse was scarce. Until now no intoxications have been reported in the EU and no centralised legal actions have been taken to prevent possible intoxications.

Conclusions: The lack of observed intoxications may justify the absence of legal actions in the EU against phenethylamine designer drugs-of-abuse of the 2C-series. However, this may also be explained by either the inability of toxicologists to detect the abuse of substances of the 2C-series or the unawareness of the phenomenon of these drugs. Therefore, EU authorities should promote the availability of relevant standards, validated assays and scientific knowledge regarding these drugs.

2C-B, 2C-T-2, 2C-T-7 Designer drugs-of-abuse Ecstasy Smartdrug Smartshop 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Henderson GL. Designer drugs. In: Brandenberg H, Maes RAA, editors. Analytical toxicology for clinical, forensic and pharmaceutical chemists. Berlin: de Gruyter, 1997; 685-704.Google Scholar
  2. 2.
    Kronstrand R. Identification of N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) in urine from drug abusers. J Anal Tox 1996; 20: 512-6.Google Scholar
  3. 3.
    De Boer D, Egberts T, Maes RA. Para-methylthioamphetamine, a new amphetamine designer drug of abuse. Pharm World Sci 1999; 21: 47-8.Google Scholar
  4. 4.
    Report on the risk assessment of 4-PMMA in the framework of the joint action on new synthetic drugs. Lisbon: EMCDDA, 2002.Google Scholar
  5. 5.
    Delliou D. 4-Bromo-2,5-dimethoxyamphetamine: psychoactivity, toxic effects and analytical methods. Forensic Sci Int 1983; 21: 259-67.Google Scholar
  6. 6.
    Felgate HE, Felgate PD, James RA, Sims DN, Vozzo DC. Recent paramethoxyamphetamine deaths. J Anal Tox 1998; 22: 169-72.Google Scholar
  7. 7.
    Shulgin A, Shulgin A. PIHKAL: A chemical love story. Berkeley, California: Transform Press, 1991.Google Scholar
  8. 8.
    Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J Med Chem 1996; 39: 2953-61.Google Scholar
  9. 9.
    De Boer D, Gijzels MJ, Bosman IJ, Maes RA. More data about the new psychoactive drug 2C-B. J Anal Tox 1999; 23: 227-8.Google Scholar
  10. 10.
    Bosman IJ, Siderius EB, De Boer D, Dos Reys LJAL, Maes RAA. Mass spectrometric identification of some sulphur-containing phenalkylamine designer drugs. In: Joint SOFT/TIAFT International Meeting [Proceedings] 1998; 355-7. (Errata appear in Problems Forensic Sci 2000; XLII: 215-9.)Google Scholar
  11. 11.
    Consumentenbond. Legale drugs zijn ook link. Consumentengids 1998; 46: 4.Google Scholar
  12. 12.
    Stolaroff MJ, Wells CW. Preliminary results with new psychoactive agents 2C-T-2 and 2C-T-7. Jahrbuch für Ethnomedizin und Bewußtseinsforschung. Berlin: VWB, 1993; 2: 99-117.Google Scholar
  13. 13.
    Jacob III P, Shulgin AT. Structure-activity relationships of the classic hallucinogens and their analogs. In: Lin GC, Glennon RA, editors. Hallucinogens: An Update. NIDA Res Monograph 1994; 146: 74-91.Google Scholar
  14. 14.
    Shulgin A, Shulgin A. Barriers to research. Jahrbuch für Ethnomedizin und Bewußtseinsforschung. Berlin: VWB, 1993; 2: 9-20.Google Scholar
  15. 15.
    Giroud C, Augsburger M, Rivier L, Mangin P, Sadeghipour F, Varesio E et al. 2C-B: a new psychoactive phenethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. J Anal Tox 1998; 22: 345-54.Google Scholar
  16. 16.
    Report on the risk assessment of 4-MTA in the framework of the joint action on new synthetic drugs. Lisbon: EMCDDA, 1999.Google Scholar
  17. 17.
    2C-B (Nexus) reappears on the club drug scene. Information Bulletin US Department of Justice, product no. 2001-L0424-002, DEA 2001.Google Scholar
  18. 18.
    2001 Annual report on the state of drugs problem in the European Union. Lisbon: EMCDDA, 2001.Google Scholar
  19. 19.
    Carter N, Rutty GN, Milroy CM, Forrest AR. Deaths associated with MBDB misuse. Int J Legal Med 2000; 113: 168-70.Google Scholar
  20. 20.
    Report on the risk assessment of MBDB in the framework of the joint action on new synthetic drugs. Lisbon: EMCDDA, 1999.Google Scholar
  21. 21.
    DEA's Office of Diversion Control, Drug and Chemical Evaluation Section. Request for information — BZP, TFMPP, and 2C-T-7. Microgram 2002; XXXV: 122-3.Google Scholar
  22. 22.
    Curtis B, Harty L, Kemp P, Choi C, Sneed G, Christensen D. Preliminary investigation into identification and quantitation of 2,5-dimethoxy-n-propylthiophenethylamine also known as 2C-T-7. In: Fall Meeting of the Southwestern Association of Toxicologists, 1–3 November 2001, San Antonio, Texas. Retrieved from on 15 June 2002.Google Scholar
  23. 23.
    Zimmermann MM. The identification of 2,5-dimethoxy-(n)-propylthiophenethylamine (2C-T-7). Microgram 2001; XXXIV: 169-73.Google Scholar
  24. 24.
    Poortman AJ. The synthesis of 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2). J Cland Lab Invest Chem Assoc 1999; 9: 17-20.Google Scholar
  25. 25.
    Katagi M, Tsuchihashi H. Update on clandestine amphetamines and their analogues recently seen in Japan. J Health Sc 2002; 48: 14-21.Google Scholar
  26. 26.
    De Boer D, Dos Reys LJAL, Pylon N, Gijzels M, Bosman IJ, Maes RAA. Preliminary results on the urinary excretion of 2C-B (4-bromo-2,5-dimethoxyphenethylamine) and its metabolites in humans. Br J Pharmacol 1999; 127: 41P.Google Scholar
  27. 27.
    Kanamori T, Inoue H, Iwata Y, Ohmae Y, Kishi T. In vivo metabolism of 4-bromo-2,5-dimethoxy-phenethylamine (2C-B) in the rat: identification of urinary metabolites. J Anal Tox 2002; 26: 61-6.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Douwe de Boer
    • 1
  • Ingrid Bosman
    • 2
    • 2
  1. 1.Instituto Nacional do Desporto, Laboratório de Análises de Dopagem e Bioquímica, Av. Prof. Egas Moniz(Estádio Universitário)LisbonPortugal
  2. 2.Department of Human Toxicology, Institute for Pharmaceutical Sciences (UIPS)University of UtrechtThe Netherlands

Personalised recommendations